|
|
Upfront Briefing
Grail took a hit in the UK after a study said its cancer detection test missed the primary endpoint — the kind of readout that can reset adoption math when your commercialization plan rhymes with “screening-scale.”
On the flip side of the roulette wheel: FDA just greenlit Venclexta (venetoclax) + acalabrutinib in frontline CLL — an all-oral, fixed-duration angle that matters in a crowded 1L landscape. And on capital: Candel stacked $100M of royalty funding with a $100M public offering — keep the runway long, keep the clock running.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,861.9 |
(0.3%) |
+0.2% |
| Nasdaq 100 |
24,797.3 |
(0.4%) |
(1.8%) |
| Russell 2000 |
2,665.1 |
+0.2% |
+7.4% |
| Healthcare (XLV) |
157.3 |
(0.3%) |
+1.6% |
| Biotech (XBI) |
126.7 |
+0.9% |
+3.9% |
| Nasdaq Biotech (NBI) |
6,010.6 |
+0.2% |
+5.3% |
| Clinical Trials (BBC) |
41.4 |
+0.9% |
+7.4% |
|
-
Biotech outperformed a softer tape: XBI +0.9% even as the S&P 500 slipped (0.3%), as idiosyncratic catalysts (FDA labels, financings) pulled flows into the sector despite broader macro/mega-cap caution.
-
Small-cap beta showed up inside biotech: XBI +0.9% and BBC +0.9% moved in sync — a pattern you tend to see when risk appetite is “selective,” not outright risk-off.
-
Market data: U.S. close Thu 19-Feb-2026.
The Big 3
|
1
|
Grail cancer test misses primary endpoint in UK study
|
- A UK study reported that Grail's cancer detection test missed its primary goal. The setback could reset adoption assumptions tied to screening-scale commercialization.
-
Why it matters:
The NHS-linked dataset was supposed to be “real-world-scale” validation for MCED screening — and missing the primary endpoint forces investors to re-underwrite (1) the adoption curve, (2) the reimbursement/evidence pathway, and (3) the timeline to population-level screening economics. In practice, this typically means slower penetration assumptions, higher evidence spend, and a longer path to durable payor coverage — all of which compress near-term conviction in long-dated revenue ramps.
- Source: STAT
- More: Endpoints
|
|
2
|
FDA approves Venclexta plus acalabrutinib for untreated CLL
|
- FDA approved Venclexta (venetoclax) plus acalabrutinib for previously untreated chronic lymphocytic leukemia. The new frontline label reshapes positioning in oral, fixed-duration regimens.
-
Why it matters:
This is a commercially meaningful label because it creates the first all-oral, fixed-duration frontline CLL combo — a positioning advantage versus “treat-until-progression” BTK strategies. That can pull share in 1L, improve persistence of the venetoclax franchise (AbbVie/Roche), and pressure competitors on both duration and tolerability. For investors, the key model change is a larger eligible pool with a clearer “time-limited” value proposition that can support durable demand even as the 1L landscape crowds.
-
Source:
PR
|
| 3 | Candel stacks $100M royalty funding with a $100M public offering |
-
Candel Therapeutics announced pricing of its public offering after earlier launching a proposed $100 million deal. The financing could extend runway while resetting dilution expectations.
-
Why it matters:
Follow-on pricing is a live signal on small-cap biotech cost of capital: a clean raise extends runway and reduces “financing overhang,” but the print also sets a new dilution reference point for the stock (and peers) heading into catalysts. For investors, the underwriting question becomes whether incremental runway meaningfully increases the probability of value-inflecting data/filings before the next capital need.
-
Source:
PR
-
More:
PR;
PR
|
Everything Else that broke
-
FDA accepts Roche NDA for giredestrant in ESR1-mutated, ER+ advanced breast cancer. —
PR
-
Court allows AbbVie and PhRMA to proceed with a 340B case in Hawaii. —
Endpoints
-
Teva beat Corcept in an appeals fight over a generic Cushing's syndrome drug. —
Endpoints
-
In her first speech to FDA staff, Hoeg said she’ll scrutinize RSV shots and SSRIs in pregnancy. —
STAT
-
BioCentury: China weighed on a PhRMA Forum discussion and MFN legislation was also in focus. —
BioCentury
-
J&J: RYBREVANT FASPRO + immunotherapy showed a 56% ORR in 1L recurrent/metastatic head and neck cancer. —
PR
-
GRAIL reported Q4 and FY2025 financial results. —
PR
-
BioCentury: Korsana outlines “best-in-class” ambitions in the Alzheimer’s brain-shuttle race. —
BioCentury
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
No notable M&A / BD&L in the last 24 hours.
VC / Private Financings
-
Altesa BioSciences raised $75M Series B to advance vapendavir in chronic lung disease (COPD exacerbations) —
led by Forbion, joined by Sanofi; existing investors include Medicxi, Pitango, and Atlantic Partners. —
PR
(More:
Fierce)
IPOs / Follow-Ons
-
Candel Therapeutics priced a $100M public offering (separate from its $100M royalty funding agreement with RTW announced earlier). —
PR
(Royalty:
PR)
Academic Corner - Cumulative incidence of advanced breast cancer in women aged 40–49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis. — Lancet
- One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma. — NEJM
|
|
That’s all — data wins, dilution stings. See you Monday. BioBucks Team
|
|
|
